*^VLP technology underlying all candidates is licensed from the University of Washington
*Icosavax does not plan to pursue the IVX-121 RSV monovalent candidate as a standalone candidate for RSV in older adults, and plans to transition development to the IVX-A12 bivalent RSV/HMPV candidate following Phase 1. The RSV antigen incorporated into IVX-121 is licensed from the National Institutes of Health; key mutations in the hMPV antigen incorporated into IVX-A12 are licensed from the National Institute of Health and the University of Texas at Austin
^Icosavax has worldwide nonexclusive rights with exception of South Korea, along with an option to convert to exclusive rights in North America and Europe